The Acute Respiratory Distress Syndrome (ARDS) represents a common syndrome arising from numerous, heterogeneous, and often-independent disease processes. Accordingly, a single ARDS study drug, if uniformly applied to all patients regardless of underlying disease pathophysiology, would likely fail to consistently improve patient outcomes. For clinical studies to overcome this obstacle, a new appreciation of ARDS mechanistic and phenotypic heterogeneity is required, enabling future precision medicine approaches to the treatment of lung injury.
The 2021 Thomas L. Petty Aspen Lung Conference will integrate basic, translational, and clinical approaches to address the impact of ARDS heterogeneity, with a focus on (1) understanding the presence and therapeutic significance of ARDS mechanistic and phenotypic subtypes, (2) exploring multi-cellular and multi-systemic mechanisms responsible for this heterogeneity, and (3) determining how to best account for disease heterogeneity during clinical trial design and outcome assessment. Heterogeneity within COVID-19 ARDS, as well as between COVID-19 and non-COVID-19 ARDS, will also be discussed.
This conference will provide an international forum bringing together leading basic, translational, and clinical ARDS researchers while welcoming trainees in pulmonology and critical care medicine, with the goal of identifying shared interests that will lead to more productive research and more effective personalized therapies. Finally, the varied scientific themes and therapeutic strategies emerging during the conference will be reconciled in a concluding Conference Summary presented by Dr. Thomas Martin (University of Washington).
We will offer three Thomas L. Petty Fellow Travel Awards in the amount of $1,000 each to three female and under-represented minority fellows whose abstracts have been accepted for podium presentations.
In summary, the conference distinguishes itself from other conference in this field by serving as a “think tank” to actively discuss the current state of the field and identify the future directions for basic, translational and clinical research in ARDS.
For more information, contact: Eric Schmidt, M.D., c/o Jeanne Cleary, Thomas L. Petty Aspen Lung Conference, PO Box 1231, Parker, CO 80134 Phone: (303) 358-2797. E-Mail: Jeanne.Cleary@cuanschutz.edu.
The 2021 Aspen Lung Conference has the following learning objectives:
At the conclusion of this conference attendees will be able to:
ARDS in the 21st Century: New Insights into Clinical and Mechanistic Heterogeneity
September 20-23, 2021
Bridging the Gap between Innate and Adaptive Immunity in the Lung
June 8-11, 2022